Minireview: The molecular and genomic basis for prostate cancer health disparities

Molecular Endocrinology

Volumn 27, Issue 6, 2013, Pages 879-891

  Powell, Isaac J ^a   Bollig Fischer, Aliccia ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; CYTOCHROME P450 1B1; CYTOCHROME P450 3A4; EPHRIN RECEPTOR B2; EPIDERMAL GROWTH FACTOR RECEPTOR; GLUTATHIONE TRANSFERASE; POLYCYCLIC AROMATIC HYDROCARBON; TRANSCRIPTOME; VITAMIN D RECEPTOR;

CANCER GENETICS; CANCER GROWTH; CANCER SIZE; CANCER STAGING; CARCINOGENESIS; CHROMOSOME 8Q; CHROMOSOME DELETION; COPY NUMBER VARIATION; DNA DAMAGE; EPIGENETICS; ETHNICITY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE LOSS; GENE REARRANGEMENT; GENETIC ASSOCIATION; GENETIC GAIN; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC VARIABILITY; GENOMICS; HEALTH DISPARITY; HUMAN; HYPERTENSION; INFLAMMATION; MISSENSE MUTATION; MOLECULAR GENETICS; OBESITY; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN PROCESSING; RACE DIFFERENCE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE;

AFRICAN AMERICANS; EPIGENESIS, GENETIC; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HEALTH SERVICES ACCESSIBILITY; HUMANS; MALE; MUTATION; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; RISK FACTORS; SOCIOECONOMIC FACTORS; UNITED STATES;

EID: 84877892978     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2013-1039     Document Type: Review

References (111)

1. Horner M, Ries L, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2006. Bethesda, Maryland: National Cancer Institute; 2009
2. Odedina FT, Akinremi TO, Chinegwundoh F, et al. Prostate cancer disparities in Black men of African descent: a comparative literature review of prostate cancer burden among Black men in the United States, Caribbean, United Kingdom, and West Africa. Infect Agent Cancer. 2009;4(suppl 1):S2
3. Behavioral Risk Factor Surveillance System. Behavioral risk factor surveillance system survey data. In: Prevention CfDCa. Atlanta, Georgia: United States Department of Health and Human Services, Centers for Disease Control and Prevention; 2009
4. Du XL, Fang S, Coker AL, et al. Racial disparity and socioeconomic status in association with survival in older men with local/regional stage prostate carcinoma: findings from a large community-based cohort. Cancer. 2006;106(6):1276-1285
5. Dash A, Lee P, Zhou Q, et al. The impact of socioeconomic factors on prostate cancer outcomes in black patients treated with surgery. Urology. 2008;72(3):641
6. Powell IJ, Heilbrun LK, Sakr W, et al. The predictive value of race as a clinical prognostic factor among patients with clinically localized prostate cancer: a multivariate analysis of positive surgical margins. Urology. 1997;49(5):726-731
7. Powell IJ, Banerjee M, Sakr W, et al. Should African-American men be tested for prostate carcinoma at an earlier age than white men? Cancer. 1999;85(2):472-477
8. Powell IJ, Bock CH, Ruterbusch JJ, Sakr W. Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. J Urol. 2010; 183(5):1792
9. Waxman DJ, Lapenson DP, Aoyama T, Gelboin HV, Gonzalez FJ, Korzekwa K. Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Arch Biochem Biophys. 1991;290(1):160-166
10. Ozdemir V, Kalow W, Tang BK, et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics. 2000;10(5):373-388
11. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst. 1998;90(16):1225-1229
12. Paris PL, Kupelian PA, Hall JM, et al. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol Biomarkers Prev. 1999;8(10):901-905
13. Powell IJ, Zhou J, Sun Y, et al. CYP3A4 genetic variant and diseasefree survival among white and black men after radical prostatectomy. J Urol. 2004;172(5):1848-1852
14. Wacholder S, Rothman N, Caporaso N. Counterpoint: bias from population stratification is not a major threat to the validity of conclusions from epidemiological studies of common polymorphisms and cancer. Cancer Epidemiol Biomarkers Prev. 2002; 11(6):513-520
15. Powell IJ, Banerjee M, Novallo M, et al. Prostate cancer biochemical recurrence stage for stage is more frequent among African- American than white men with locally advanced but not organconfined disease. Urology. 2000;55(2):246
16. Bangsi D, Zhou JY, Sun Y, et al. Impact of a genetic variant in CYP3A4 on risk and clinical presentation of prostate cancer among white and African-American men. Urol Oncol. 2006;24(1):21
17. Amundadottir LT, Sulem P, Gudmundsson J, et al. A common variant associated with prostate cancer in European and African populations. Nat Genet. 2006;38(6):652-658
18. Freedman ML, Haiman CA, Patterson N, et al. Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci USA. 2006;103(38):14068-14073
19. Haiman CA, Patterson N, Freedman ML, et al. Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet. 2007;39(5):638-644
20. Bock CH, Schwartz AG, Ruterbusch JJ, et al. Results from a prostate cancer admixture mapping study in African-American men. Hum Genet. 2009;126(5):637-642
21. Robbins C, Torres JB, Hooker S, et al. Confirmation study of prostate cancer risk variants at 8q24 in African Americans identifies a novel risk locus. Genome Res. 2007;17(12):1717-1722
22. Helfand BT, Loeb S, Cashy J, et al. Tumor characteristics of carriers and noncarriers of the deCODE 8q24 prostate cancer susceptibility alleles. J Urol. 2008;179(6):2197-2202
23. Whitman EJ, Pomerantz M, Chen Y, et al. Prostate cancer risk allele specific for African descent associates with pathologic stage at prostatectomy. Cancer Epidemiol Biomarkers Prev. 2010;19(1):1-8
24. Chang BL, Spangler E, Gallagher S, et al. Validation of genomewide prostate cancer associations in men of African descent. Cancer Epidemiol Biomarkers Prev. 2011;20(1):23-32
25. Bensen JT, Xu Z, Smith GJ, Mohler JL, Fontham ET, Taylor JA. Genetic polymorphism and prostate cancer aggressiveness: a caseonly study of 1,536 GWAS and candidate SNPs in African-Americans and European-Americans. Prostate. 2012;.
26. Huusko P, Ponciano-Jackson D, Wolf M, et al. Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. Nat Genet. 2004;36(9):979-983
27. Kittles RA, Baffoe-Bonnie AB, Moses TY, et al. A common nonsense mutation in EphB2 is associated with prostate cancer risk in African American men with a positive family history. J Med Genet. 2006;43(6):507-511
28. Robbins CM, Hooker S, Kittles RA, Carpten JD. EphB2 SNPs and sporadic prostate cancer risk in African American men. PLoS One. 2011;6(5):e19494
29. West L, Vidwans SJ, Campbell NP, et al. A novel classification of lung cancer into molecular subtypes. PLoS One. 2012;7(2):e31906
30. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70
31. Sharma SV, Settleman J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev. 2007;21(24): 3214-3231
32. Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 2006; 439(7074):353-357
33. Barbieri CE, Baca SC, Lawrence MS, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet. 2012;44(6):685-689
34. Friedlander TW, Roy R, Tomlins SA, et al. Common structural and epigenetic changes in the genome of castration-resistant prostate cancer. Cancer Res. 2012;72(3):616-625
35. Grasso CS, Wu YM, Robinson DR, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012; 487(7406):239-243
36. Stead LA, Lash TL, Sobieraj JE, et al. Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res. 2009;11(2):R18
37. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492-2502
38. Kooiman GG, Martin FL, Williams JA, Grover PL, Phillips DH, Muir GH. The influence of dietary and environmental factors on prostate cancer risk. Prostate Cancer Prostatic Dis. 2000;3(4):256-258
39. Hemminki K, Koskinen M, Rajaniemi H, Zhao C. Dna adducts, mutations, and cancer 2000. Regul Toxicol Pharmacol. 2000; 32(3):264-275
40. Nock NL, Tang D, Rundle A, et al. Associations between smoking, polymorphisms in polycyclic aromatic hydrocarbon (PAH) metabolism and conjugation genes and PAH-DNA adducts in prostate tumors differ by race. Cancer Epidemiol Biomarkers Prev. 2007; 16(6):1236-1245
41. Tang D, Kryvenko ON, Wang Y, et al. Elevated polycyclic aromatic hydrocarbon-DNA adducts in benign prostate and risk of prostate cancer in African Americans. Carcinogenesis. 2013;34(1):113-120
42. Nock NL, Bock C, Neslund-Dudas C, et al. Polymorphisms in glutathione S-transferase genes increase risk of prostate cancer biochemical recurrence differentially by ethnicity and disease severity. Cancer Causes Control. 2009;20(10):1915-1926
43. Watters JL, Satia JA, Kupper LL, Swenberg JA, Schroeder JC, Switzer BR. Associations of antioxidant nutrients and oxidative DNA damage in healthy African-American and White adults. Cancer Epidemiol Biomarkers Prev. 2007;16(7):1428-1436
44. Yang ZQ, Liu G, Bollig-Fischer A, Haddad R, Tarca AL, Ethier SP. Methylation-associated silencing of SFRP1 with an 8p11-12 amplification inhibits canonical and non-canonical WNT pathways in breast cancers. Int J Cancer. 2009;125(7):1613-1621
45. Cher ML, Lewis PE, Banerjee M, et al. A similar pattern of chromosomal alterations in prostate cancers from African-Americans and Caucasian Americans. Clin Cancer Res. 1998;4(5):1273-1278
46. Cher ML, Bova GS, Moore DH, et al. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res. 1996;56(13):3091-3102
47. Castro P, Creighton CJ, Ozen M, Berel D, Mims MP, Ittmann M. Genomic profiling of prostate cancers from African American men. Neoplasia. 2009;11(3):305-312
48. Rose AE, Satagopan JM, Oddoux C, et al. Copy number and gene expression differences between African American and Caucasian American prostate cancer. J Transl Med. 2010;8:70
49. Berger MF, Lawrence MS, Demichelis F, et al. The genomic complexity of primary human prostate cancer. Nature. 2011; 470(7333):214-220
50. Tomlins SA, Laxman B, Dhanasekaran SM, et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature. 2007;448(7153):595-599
51. Mehra R, Tomlins SA, Shen R, et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol. 2007;20(5):538-544
52. Magi-Galluzzi C, Tsusuki T, Elson P, et al. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. Prostate. 2011;71(5):489-497
53. Borno ST, Fischer A, Kerick M, et al. Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation. Cancer Discov. 2012;2(11):1024-1035
54. Powell I, Dyson G, Land S, et al. Genes associated with prostate cancer are differentially expresed in African American and European American men [published online March 20, 2013]. Cancer Epidemiol Biomarkers Prev. doi:10.1158/1055-9965.EPI-12- 1238
55. Rosen P, Pfister D, Young D, et al. Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer. Urology. 2012; 80(4):749-753
56. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150(1):12-27
57. Kanwal R, Pandey M, Bhaskaran N, et al. Protection against oxidative DNA damage and stress in human prostate by glutathione S-transferase P1. Mol Carcinog. 2012;.
58. Kwabi-Addo B, Wang S, Chung W, et al. Identification of differentially methylated genes in normal prostate tissues from African American and Caucasian men. Clin Cancer Res. 2010;16(14): 3539-3547
59. Yegnasubramanian S, Kowalski J, Gonzalgo ML, et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res. 2004;64(6):1975-1986
60. Woodson K, Hayes R, Wideroff L, Villaruz L, Tangrea J. Hypermethylation of GSTP1, CD44, and E-cadherin genes in prostate cancer among US Blacks and Whites. Prostate. 2003;55(3):199-205
61. Nelson WG, De Marzo AM, Yegnasubramanian S. Epigenetic alterations in human prostate cancers. Endocrinology. 2009;150(9): 3991-4002
62. Major JM, Norman Oliver M, Doubeni CA, Hollenbeck AR, Graubard BI, Sinha R. Socioeconomic status, healthcare density, and risk of prostate cancer among African American and Caucasian men in a large prospective study. Cancer Causes Control. 2012; 23(7):1185-1191
63. Hsing AW, Sakoda LC, Chua S Jr. Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr. 2007;86(3):s843-s857
64. Parker PM, Rice KR, Sterbis JR, et al. Prostate cancer in men less than the age of 50: a comparison of race and outcomes. Urology. 2011;78(1):110-115
65. Shuch B, Mikhail M, Satagopan J, et al. Racial disparity of epidermal growth factor receptor expression in prostate cancer. J Clin Oncol. 2004;22(23):4725-4729
66. Di Lorenzo G, Tortora G, D'Armiento FP, et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res. 2002;8(11):3438-3444
67. Sherwood ER, Van Dongen JL, Wood CG, Liao S, Kozlowski JM, Lee C. Epidermal growth factor receptor activation in androgenindependent but not androgen-stimulated growth of human prostatic carcinoma cells. Br J Cancer. 1998;77(6):855-861
68. Torring N, Dagnaes-Hansen F, Sorensen BS, Nexo E, Hynes NE. ErbB1 and prostate cancer: ErbB1 activity is essential for androgeninduced proliferation and protection from the apoptotic effects of LY294002. Prostate. 2003;56(2):142-149
69. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res. 2000;6(12):4885-4892
70. Sirotnak FM, She Y, Lee F, Chen J, Scher HI. Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer. Clin Cancer Res. 2002;8(12):3870-3876
71. Agus DB, Akita RW, Fox WD, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell. 2002;2(2):127-137
72. Douglas DA, Zhong H, Ro JY, et al. Novel mutations of epidermal growth factor receptor in localized prostate cancer. Front Biosci. 2006;11:2518-2525
73. Cote ML, Haddad R, Edwards DJ, et al. Frequency and type of epidermal growth factor receptor mutations in African Americans with non-small cell lung cancer. J Thorac Oncol. 2011;6(3):627-630
74. Canil CM, Moore MJ, Winquist E, et al. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol. 2005;23(3):455-460
75. Reams RR, Agrawal D, Davis MB, et al. Microarray comparison of prostate tumor gene expression in African-American and Caucasian American males: a pilot project study. Infect Agent Cancer. 2009;4(suppl 1):S3
76. Wallace TA, Prueitt RL, Yi M, et al. Tumor immunobiological differences in prostate cancer between African-American and European- American men. Cancer Res. 2008;68(3):927-936
77. Petrovics G, Zhang W, Makarem M, et al. Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients. Oncogene. 2004;23(2):605-611
78. Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol. 2002;20(13):3001-3015
79. Gaston KE, Kim D, Singh S, Ford OH 3rd, Mohler JL. Racial differences in androgen receptor protein expression in men with clinically localized prostate cancer. J Urol. 2003;170(3):990-993
80. La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature. 1991;352(6330):77-79
81. Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res. 1994; 22(15):3181-3186
82. Lim HN, Chen H, McBride S, et al. Longer polyglutamine tracts in the androgen receptor are associated with moderate to severe undermasculinized genitalia in XY males. Hum Mol Genet. 2000; 9(5):829-834
83. Bennett CL, Price DK, Kim S, et al. Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic status. J Clin Oncol. 2002;20(17): 3599-3604
84. Sartor O, Zheng Q, Eastham JA. Androgen receptor gene CAG repeat length varies in a race-specific fashion in men without prostate cancer. Urology. 1999;53(2):378-380
85. Gilligan T, Manola J, Sartor O, Weinrich SP, Moul JW, Kantoff PW. Absence of a correlation of androgen receptor gene CAG repeat length and prostate cancer risk in an African-American population. Clin Prostate Cancer. 2004;3(2):98-103
86. Giovannucci E, Stampfer MJ, Krithivas K, et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA. 1997;94(7):3320-3323
87. Chen C, Lamharzi N, Weiss NS, et al. Androgen receptor polymorphisms and the incidence of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2002;11(10 pt 1):1033-1040
88. Powell IJ, Land SJ, Dey J, et al. The impact of CAG repeats in exon 1 of the androgen receptor on disease progression after prostatectomy. Cancer. 2005;103(3):528-537
89. Lindstrom S, Ma J, Altshuler D, et al. A large study of androgen receptor germline variants and their relation to sex hormone levels and prostate cancer risk. Results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. J Clin Endocrinol Metab. 2010;95(9):E121-E127
90. Lapointe J, Li C, Giacomini CP, et al. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res. 2007;67(18):8504-8510
91. Wang BD, Yang Q, Ceniccola K, et al. Androgen receptor-target genes in african american prostate cancer disparities. Prostate Cancer. 2013;2013:763569
92. Li Y, Hwang TH, Oseth LA, et al. AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression. Oncogene. 2012
93. Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers CL. HER2/neu kinase-dependent modulation of androgen receptor function through effects onDNAbinding and stability. Cancer Cell. 2004;6(5):517-527
94. Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone- independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med. 1999;5(3):280-285
95. Chan SC, Li Y, Dehm SM. Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal. J Biol Chem. 2012;287(23):19736-19749
96. Hu R, Dunn TA, Wei S, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormonerefractory prostate cancer. Cancer Res. 2009;69(1):16-22
97. Mahajan NP, Liu Y, Majumder S, et al. Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proc Natl Acad Sci USA. 2007; 104(20):8438-8443
98. Shui IM, Mucci LA, Kraft P, et al. Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study. J Natl Cancer Inst. 2012;104(9): 690-699
99. Signorello LB, Williams SM, Zheng W, et al. Blood vitamin d levels in relation to genetic estimation of African ancestry. Cancer Epidemiol Biomarkers Prev. 2010;19(9):2325-2331
100. Williams H, Powell IJ, Land SJ, et al. Vitamin D receptor gene polymorphisms and disease free survival after radical prostatectomy. Prostate. 2004;61(3):267-275
101. Wang D, Zavadil J, Martin L, et al. Inhibition of nonsense-mediated RNA decay by the tumor microenvironment promotes tumorigenesis. Mol Cell Biol. 2011;31(17):3670-3680
102. Lescarbeau RM, Seib FP, Prewitz M, Werner C, Kaplan DL. In vitro model of metastasis to bone marrow mediates prostate cancer castration resistant growth through paracrine and extracellular matrix factors. PLoS One. 2012;7(8):e40372
103. Jia Z, Wang Y, Sawyers A, et al. Diagnosis of prostate cancer using differentially expressed genes in stroma. Cancer Res. 2011;71(7): 2476-2487
104. Joesting MS, Perrin S, Elenbaas B, et al. Identification of SFRP1 as a candidate mediator of stromal-to-epithelial signaling in prostate cancer. Cancer Res. 2005;65(22):10423-10430
105. Haiman CA, Chen GK, Blot WJ, et al. Characterizing genetic risk at known prostate cancer susceptibility loci in African Americans. PLoS Genet. 2011;7(5):e1001387
106. Whittemore AS, Lele C, Friedman GD, Stamey T, Vogelman JH, Orentreich N. Prostate-specific antigen as predictor of prostate cancer in black men and white men. J Natl Cancer Inst. 1995; 87(5):354-360
107. Gokce N, Holbrook M, Duffy SJ, et al. Effects of race and hypertension on flow-mediated and nitroglycerin-mediated dilation of the brachial artery. Hypertension. 2001;38(6):1349-1354
108. Amling CL, Riffenburgh RH, Sun L, et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol. 2004; 22(3):439-445
109. Hursting SD, Nunez NP, Varticovski L, Vinson C. The obesitycancer link: lessons learned from a fatless mouse. Cancer Res. 2007;67(6):2391-2393
110. Huang M, Narita S, Numakura K, et al. A high-fat diet enhances proliferation of prostate cancer cells and activates MCP-1/CCR2 signaling. Prostate. 2012;72(16):1779-1788
111. Nguyen PL, Ma J, Chavarro JE, et al. Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival. J Clin Oncol. 2010;28(25):3958-3964.